Literature DB >> 19776173

Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells.

Luciene R Carraro-Lacroix1, Gerhard Malnic, Adriana C C Girardi.   

Abstract

The gut incretin hormone glucagon-like peptide 1 (GLP-1) is released in response to ingested nutrients and enhances insulin secretion. In addition to its insulinotropic properties, GLP-1 has been shown to have natriuretic actions paralleled by a diminished proton secretion. We therefore studied the role of the GLP-1 receptor agonist exendin-4 in modulating the activity of Na(+)/H(+) exchanger NHE3 in LLC-PK(1) cells. We found that NHE3-mediated Na(+)-dependent intracellular pH (pH(i)) recovery decreased approximately 50% after 30-min treatment with 1 nM exendin-4. Pharmacological inhibitors and cAMP analogs that selectively activate protein kinase A (PKA) or the exchange protein directly activated by cAMP (EPAC) demonstrated that regulation of NHE3 activity by exendin-4 requires activation of both cAMP downstream effectors. This conclusion was based on the following observations: 1) the PKA antagonist H-89 completely prevented the effect of the PKA activator but only partially blocked the exendin-4-induced NHE3 inhibition; 2) the MEK1/2 inhibitor U-0126 abolished the effect of the EPAC activator but only diminished the exendin-4-induced NHE3 inhibition; 3) combination of H-89 and U-0126 fully prevented the effect of exendin-4 on NHE3; 4) no additive effect in the inhibition of NHE3 activity was observed when exendin-4, PKA, and EPAC activators were used together. Mechanistically, the inhibitory effect of exendin-4 on pH(i) recovery was associated with an increase of NHE3 phosphorylation. Conversely, this inhibition took place without changes in the surface expression of the transporter. We conclude that GLP-1 receptor agonists modulate sodium homeostasis in the kidney, most likely by affecting NHE3 activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19776173     DOI: 10.1152/ajprenal.00082.2009

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  45 in total

Review 1.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

Review 2.  Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.

Authors:  Chris de Graaf; Dan Donnelly; Denise Wootten; Jesper Lau; Patrick M Sexton; Laurence J Miller; Jung-Mo Ahn; Jiayu Liao; Madeleine M Fletcher; Dehua Yang; Alastair J H Brown; Caihong Zhou; Jiejie Deng; Ming-Wei Wang
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

Review 3.  GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side.

Authors:  Brad P Dieter; Radica Z Alicic; Katherine R Tuttle
Journal:  Am J Physiol Renal Physiol       Date:  2018-08-15

Review 4.  Regulation of nephron water and electrolyte transport by adenylyl cyclases.

Authors:  Timo Rieg; Donald E Kohan
Journal:  Am J Physiol Renal Physiol       Date:  2014-01-29

5.  The renoprotective effect and safety of a DPP-4 inhibitor, sitagliptin, at a small dose in type 2 diabetic patients with a renal dysfunction when changed from other DPP-4 inhibitors: REAL trial.

Authors:  Koichi Kanozawa; Yuichi Noguchi; Souichi Sugahara; Satoko Nakamura; Hirohisa Yamamoto; Keiko Kaneko; Rika Kono; Saeko Sato; Tomonari Ogawa; Hajime Hasegawa; Shigehiro Katayama
Journal:  Clin Exp Nephrol       Date:  2017-12-23       Impact factor: 2.801

Review 6.  Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development.

Authors:  William G Robichaux; Xiaodong Cheng
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

Review 7.  Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies.

Authors:  F Giorgino; A Leonardini; A Natalicchio; L Laviola
Journal:  J Endocrinol Invest       Date:  2011-01-13       Impact factor: 4.256

8.  Glucagon-like peptide-1 receptor pathway inhibits extracellular matrix production by mesangial cells through store-operated Ca2+ channel.

Authors:  Linjing Huang; Rong Ma; Tingting Lin; Sarika Chaudhari; Parisa Y Shotorbani; Liyong Yang; Peiwen Wu
Journal:  Exp Biol Med (Maywood)       Date:  2019-09-11

Review 9.  Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?

Authors:  Mikkel Christensen; Filip K Knop
Journal:  Curr Diab Rep       Date:  2010-04       Impact factor: 4.810

Review 10.  The evolving place of incretin-based therapies in type 2 diabetes.

Authors:  Baptist Gallwitz
Journal:  Pediatr Nephrol       Date:  2010-02-04       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.